Life expectancy in rare histological prostate cancer subtypes
International Journal of Cancer · 15.06.2025 · 156 (12) · 2311-2319
DOI: 10.1002/ijc.35323 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 30.12.2024. Verfasst von Carolin Siech und 17 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Life Expectancy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Survival differences in rare histological prostate cancer (PCa) subtypes relative to age‐matched population‐based controls are unknown. Within Surveillance, Epidemiology, and End Results database (2004–2020), newly diagnosed (2004–2015) PCa patients were identified. Relying on the Social Security Administration Life Tables (2004–2020) with 5 years of follow‐up, age‐matched population‐based controls (Monte Carlo simulation) were simulated for each patient. Kaplan–Meier analyses addressed survival rates. Of 582,220 patients, 580,368 (99.68%) harbored acinar, 867 (0.15%) ductal, 534 (0.09%) neuroendocrine, 368 (0.07%) mucinous, and 83 (0.01%) signet ring cell carcinoma. The metastatic stage was most prevalent in neuroendocrine (62%). In the localized stage, the overall survival difference at 5 years of follow‐up was greatest in neuroendocrine (22% vs. 72%), signet ring cell (78% vs. 84%), and ductal carcinoma (71% vs. 77%). In the locally advanced stage, overall survival difference was greatest in neuroendocrine (16% vs. 79%), signet ring cell (75% vs. 91%), ductal (78% vs. 84%), and mucinous carcinoma (84% vs. 90%). In the metastatic stage, the overall survival difference was greatest in neuroendocrine (3% vs. 81%), mucinous (26% vs. 84%), and acinar carcinoma (27% vs. 85%). Regardless of stage, neuroendocrine carcinoma patients exhibit the least favorable life expectancy compared with population‐based controls. Conversely, all other rare histological PCa subtypes do not meaningfully affect life expectancy in localized or locally advanced stages, except for locally advanced signet ring cell adenocarcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
- Department of Urology, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany.
- Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
- Vita-Salute San Raffaele University, Milan, Italy.
- Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
- Università degli Studi di Milano, Milan, Italy.
ORCID-Profile: Carolin Siech, Letizia Maria Ippolita Jannello, Francesco Di Bello, Natali Rodriguez Peñaranda
Zitieren
APA
Siech, C., de Angelis, M., Jannello, L. M. I., Di Bello, F., Rodriguez Peñaranda, N., Goyal, J. A., Tian, Z., Saad, F., Shariat, S. F., Puliatti, S., Longo, N., de Cobelli, O., Briganti, A., Wenzel, M., Mandel, P., Kluth, L. A., Chun, F. K. H., & Karakiewicz, P. I. (2025). Life expectancy in rare histological prostate cancer subtypes. International Journal of Cancer, 156(12), 2311-2319. https://doi.org/10.1002/ijc.35323
Vancouver
Siech C, de Angelis M, Jannello LMI, Di Bello F, Rodriguez Peñaranda N, Goyal JA, et al. Life expectancy in rare histological prostate cancer subtypes. International Journal of Cancer. 2025;156(12):2311-2319. doi:10.1002/ijc.35323
BibTeX
@article{Siech2025,
author = {Siech, Carolin and de Angelis, Mario and Jannello, Letizia Maria Ippolita and Di Bello, Francesco and Rodriguez Peñaranda, Natali and Goyal, Jordan A and Tian, Zhe and Saad, Fred and Shariat, Shahrokh F and Puliatti, Stefano and Longo, Nicola and de Cobelli, Ottavio and Briganti, Alberto and Wenzel, Mike and Mandel, Philipp and Kluth, Luis A and Chun, Felix K H and Karakiewicz, Pierre I},
title = {Life expectancy in rare histological prostate cancer subtypes},
journal = {International Journal of Cancer},
year = {2025},
volume = {156},
number = {12},
pages = {2311--2319},
doi = {10.1002/ijc.35323}
}
EUVIMED